Table 2.

MSH6 and MGMT immunohistochemical analysis

Treatment modalityPre- and post-treatment sample IDPretreatment MGMTPost–XRT + temozolomide MGMTPretreatment MSH6Post–XRT + temozolomide MSH6
XRT + temozolomidexT4981/xT5089+++
xT3546/xT4717++++++
xT4142/xT3692+++++
xT3559/xT4328+++++
xT2989/xT3296++++
xT4107/xT3648+++++++
xT4106/xT3307++++++
xT3506/xT3768+++++++
xT4170/xT4987+++
xT4213/xT4869++++
xT4901/xT4899++++
xT4991/xT3017+++
xT3495/xT4161++++
xT3893/xT4870n/s++
xT3513/xT4718+
xT4136/xT4900+++++
xT4838/xT5065+++++
XRT + temozolomide—/xT104+++
—/xT5046n/s
—/xT4803
—/xT3162
XRT-only—/xT4986++
—/xT4903++
—/xT4977++
—/xT4975+++
—/xT2422+++
—/xT2703++
—/xT3303+++
—/xT4985+++
  • NOTE: MSH6 and MGMT status in matched samples from 17 patients' pre– and post–XRT + temozolomide surgical resections. Additionally listed are four post–XRT + temozolomide and eight post–XRT-only samples where the pretreatment sample was unavailable for study. MSH6 scored with a system of −, nil or scant staining; +, <10% of cells stained positive in the nucleus; ++, 10% to 50%; and +++, >50% positive. MGMT scored using +, >20% positive staining; −, <20% staining.

    Abbreviation: n/s, assay not successfully done.